BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30
Posted on: Thursday, 9 April 2009, 08:00 CDT
U.S. / Canada Dial-in Number: 866.383.7998 International Dial-in Number: 617.597.5329 Participant Code: 63957862 Replay Dial-in Number: 888.286.8010 Replay International Dial-in Number: 617.801.6888 Replay Code: 48152268
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt,
BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.
Contacts: Investors Media Eugenia Shen Susan Berg BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 506-6570 (415) 506-6594
SOURCE BioMarin Pharmaceutical Inc.
Source: PR Newswire
Related Articles
- Noble Energy Starts Production From Second Phase of Dumbarton Development
- Anthony Clarke, PhD Joins Alexza Pharmaceuticals As Vice President, International Development Operations
- Jerini Ophthalmic and PR Pharmaceuticals Sign Collaboration Agreement to Develop Sustained-Release Formulations for the Treatment of Eye Diseases
- Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
- BioSante Pharmaceuticals to Host Conference Call Providing LibiGel(R) Clinical Development Update
- CollaGenex Pharmaceuticals and QuatRx Pharmaceuticals Announce Agreement for the Development and Commercialization of Becocalcidiol
- Triton American Energy Remains on Schedule for Production of Well Numbers 30 and 35
- Michael J. Taylor Joins Alexza Pharmaceuticals As Vice President, Preclinical Development
- Michael Adam, Ph.D. To Join Anadys Pharmaceuticals As Senior Vice President, Development Operations
- Elite Pharmaceuticals to Host Conference Call to Review Company Developments
 |
 |
User Comments (0)
RSS Feeds